Current List of HHS-Certified Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies, 37508-37509 [2018-16440]
Download as PDF
37508
Federal Register / Vol. 83, No. 148 / Wednesday, August 1, 2018 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Current List of HHS-Certified
Laboratories and Instrumented Initial
Testing Facilities Which Meet Minimum
Standards To Engage in Urine Drug
Testing for Federal Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
The Department of Health and
Human Services (HHS) notifies federal
agencies of the laboratories and
Instrumented Initial Testing Facilities
(IITF) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines).
A notice listing all currently HHScertified laboratories and IITFs is
published in the Federal Register
during the first week of each month. If
any laboratory or IITF certification is
suspended or revoked, the laboratory or
IITF will be omitted from subsequent
lists until such time as it is restored to
full certification under the Mandatory
Guidelines.
If any laboratory or IITF has
withdrawn from the HHS National
Laboratory Certification Program (NLCP)
during the past month, it will be listed
at the end and will be omitted from the
monthly listing thereafter.
This notice is also available on the
internet at https://www.samhsa.gov/
workplace.
FOR FURTHER INFORMATION CONTACT:
Charles LoDico, Division of Workplace
Programs, SAMHSA/CSAP, 5600
Fishers Lane, Room 16N02C, Rockville,
Maryland 20857; 240–276–2600 (voice).
SUPPLEMENTARY INFORMATION: The
Department of Health and Human
Services (HHS) notifies federal agencies
of the laboratories and Instrumented
Initial Testing Facilities (IITF) currently
certified to meet the standards of the
Mandatory Guidelines for Federal
Workplace Drug Testing Programs
(Mandatory Guidelines). The Mandatory
Guidelines were first published in the
Federal Register on April 11, 1988 (53
FR 11970), and subsequently revised in
the Federal Register on June 9, 1994 (59
FR 29908); September 30, 1997 (62 FR
51118); April 13, 2004 (69 FR 19644);
November 25, 2008 (73 FR 71858);
December 10, 2008 (73 FR 75122); April
30, 2010 (75 FR 22809); and on January
23, 2017 (82 FR 7920).
The Mandatory Guidelines were
initially developed in accordance with
sradovich on DSK3GMQ082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
20:07 Jul 31, 2018
Jkt 244001
Executive Order 12564 and section 503
of Public Law 100–71. The ‘‘Mandatory
Guidelines for Federal Workplace Drug
Testing Programs,’’ as amended in the
revisions listed above, requires strict
standards that laboratories and IITFs
must meet in order to conduct drug and
specimen validity tests on urine
specimens for federal agencies.
To become certified, an applicant
laboratory or IITF must undergo three
rounds of performance testing plus an
on-site inspection. To maintain that
certification, a laboratory or IITF must
participate in a quarterly performance
testing program plus undergo periodic,
on-site inspections.
Laboratories and IITFs in the
applicant stage of certification are not to
be considered as meeting the minimum
requirements described in the HHS
Mandatory Guidelines. A HHS-certified
laboratory or IITF must have its letter of
certification from HHS/SAMHSA
(formerly: HHS/NIDA), which attests
that it has met minimum standards.
In accordance with the Mandatory
Guidelines dated January 23, 2017 (82
FR 7920), the following HHS-certified
laboratories and IITFs meet the
minimum standards to conduct drug
and specimen validity tests on urine
specimens:
HHS-Certified Instrumented Initial
Testing Facilities
Dynacare, 6628 50th Street NW,
Edmonton, AB Canada T6B 2N7, 780–
784–1190, (Formerly: GammaDynacare Medical Laboratories).
HHS-Certified Laboratories
ACM Medical Laboratory, Inc., 160
Elmgrove Park, Rochester, NY 14624,
844–486–9226.
Alere Toxicology Services, 1111 Newton
St., Gretna, LA 70053, 504–361–8989/
800–433–3823, (Formerly: Kroll
Laboratory Specialists, Inc.,
Laboratory Specialists, Inc.).
Alere Toxicology Services, 450
Southlake Blvd., Richmond, VA
23236, 804–378–9130, (Formerly:
Kroll Laboratory Specialists, Inc.,
Scientific Testing Laboratories, Inc.;
Kroll Scientific Testing Laboratories,
Inc.).
Baptist Medical Center-Toxicology
Laboratory, 11401 I–30, Little Rock,
AR 72209–7056, 501–202–2783,
(Formerly: Forensic Toxicology
Laboratory Baptist Medical Center).
Clinical Reference Laboratory, Inc., 8433
Quivira Road, Lenexa, KS, 66215–
2802, 800–445–6917.
DrugScan, Inc., 200 Precision Road,
Suite 200, Horsham, PA 19044, 800–
235–4890.
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
Dynacare*, 245 Pall Mall Street,
London, ONT, Canada N6A 1P4, 519–
679–1630, (Formerly: GammaDynacare Medical Laboratories).
ElSohly Laboratories, Inc., 5 Industrial
Park Drive, Oxford, MS 38655, 662–
236–2609.
Laboratory Corporation of America
Holdings, 7207 N Gessner Road,
Houston, TX 77040, 713–856–8288/
800–800–2387.
Laboratory Corporation of America
Holdings, 69 First Ave., Raritan, NJ
08869, 908–526–2400/800–437–4986,
(Formerly: Roche Biomedical
Laboratories, Inc.).
Laboratory Corporation of America
Holdings, 1904 TW Alexander Drive,
Research Triangle Park, NC 27709,
919–572–6900/800–833–3984,
(Formerly: LabCorp Occupational
Testing Services, Inc., CompuChem
Laboratories, Inc.; CompuChem
Laboratories, Inc., A Subsidiary of
Roche Biomedical Laboratory; Roche
CompuChem Laboratories, Inc., A
Member of the Roche Group).
Laboratory Corporation of America
Holdings, 1120 Main Street,
Southaven, MS 38671, 866–827–8042/
800–233–6339, (Formerly: LabCorp
Occupational Testing Services, Inc.;
MedExpress/National Laboratory
Center).
LabOne, Inc. d/b/a Quest Diagnostics,
10101 Renner Blvd., Lenexa, KS
66219, 913–888–3927/800–873–8845,
(Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center for
Laboratory Services, a Division of
LabOne, Inc.).
MedTox Laboratories, Inc., 402 W.
County Road D, St. Paul, MN 55112,
651–636–7466/800–832–3244.
Legacy Laboratory Services—MetroLab,
1225 NE 2nd Ave., Portland, OR
97232, 503–413–5295/800–950–5295.
Minneapolis Veterans Affairs Medical
Center, Forensic Toxicology
Laboratory, 1 Veterans Drive,
Minneapolis, MN 55417, 612–725–
2088. Testing for Veterans Affairs
(VA) Employees Only.
National Toxicology Laboratories, Inc.,
1100 California Ave., Bakersfield, CA
93304, 661–322–4250/800–350–3515.
One Source Toxicology Laboratory, Inc.,
1213 Genoa-Red Bluff, Pasadena, TX
77504, 888–747–3774, (Formerly:
University of Texas Medical Branch,
Clinical Chemistry Division; UTMB
Pathology-Toxicology Laboratory).
Pacific Toxicology Laboratories, 9348
DeSoto Ave., Chatsworth, CA 91311,
800–328–6942, (Formerly: Centinela
Hospital Airport Toxicology
Laboratory).
Pathology Associates Medical
Laboratories, 110 West Cliff Dr.,
E:\FR\FM\01AUN1.SGM
01AUN1
sradovich on DSK3GMQ082PROD with NOTICES
Federal Register / Vol. 83, No. 148 / Wednesday, August 1, 2018 / Notices
Spokane, WA 99204, 509–755–8991/
800–541–7891x7.
Phamatech, Inc., 15175 Innovation
Drive, San Diego, CA 92128, 888–
635–5840.
Quest Diagnostics Incorporated, 1777
Montreal Circle, Tucker, GA 30084,
800–729–6432, (Formerly: SmithKline
Beecham Clinical Laboratories;
SmithKline Bio-Science Laboratories).
Quest Diagnostics Incorporated, 400
Egypt Road, Norristown, PA 19403,
610–631–4600/877–642–2216,
(Formerly: SmithKline Beecham
Clinical Laboratories; SmithKline BioScience Laboratories).
Redwood Toxicology Laboratory, 3700
Westwind Blvd., Santa Rosa, CA
95403, 800–255–2159.
STERLING Reference Laboratories, 2617
East L Street, Tacoma, WA 98421,
800–442–0438.
US Army Forensic Toxicology Drug
Testing Laboratory, 2490 Wilson St.,
Fort George G. Meade, MD 20755–
5235, 301–677–7085, Testing for
Department of Defense (DoD)
Employees Only.
* The Standards Council of Canada
(SCC) voted to end its Laboratory
Accreditation Program for Substance
Abuse (LAPSA) effective May 12, 1998.
Laboratories certified through that
program were accredited to conduct
forensic urine drug testing as required
by U.S. Department of Transportation
(DOT) regulations. As of that date, the
certification of those accredited
Canadian laboratories will continue
under DOT authority. The responsibility
for conducting quarterly performance
testing plus periodic on-site inspections
of those LAPSA-accredited laboratories
was transferred to the U.S. HHS, with
the HHS’ NLCP contractor continuing to
have an active role in the performance
testing and laboratory inspection
processes. Other Canadian laboratories
wishing to be considered for the NLCP
may apply directly to the NLCP
contractor just as U.S. laboratories do.
Upon finding a Canadian laboratory to
be qualified, HHS will recommend that
DOT certify the laboratory (Federal
Register, July 16, 1996) as meeting the
minimum standards of the Mandatory
Guidelines published in the Federal
Register on January 23, 2017 (82 FR
7920). After receiving DOT certification,
the laboratory will be included in the
monthly list of HHS-certified
laboratories and participate in the NLCP
certification maintenance program.
Charles P. LoDico,
Chemist.
[FR Doc. 2018–16440 Filed 7–31–18; 8:45 am]
BILLING CODE 4160–20–P
VerDate Sep<11>2014
20:07 Jul 31, 2018
Jkt 244001
DEPARTMENT OF HOMELAND
SECURITY
U.S. Customs and Border Protection
[CBP Dec. 18–08]
COBRA Fees To Be Adjusted for
Inflation in Fiscal Year 2019
U.S. Customs and Border
Protection, Department of Homeland
Security.
ACTION: General notice.
AGENCY:
This document announces
that U.S. Customs and Border Protection
(CBP) is adjusting certain customs user
fees and limitations established by the
Consolidated Omnibus Budget
Reconciliation Act (COBRA) for Fiscal
Year 2019 in accordance with the Fixing
America’s Surface Transportation Act
(FAST Act) as implemented by CBP
regulations.
SUMMARY:
The adjusted amounts of
customs COBRA user fees and their
corresponding limitations set forth in
this notice for Fiscal Year 2019 are
required as of October 1, 2018.
FOR FURTHER INFORMATION CONTACT: Tina
Ghiladi, Director—Office of Finance,
202–344–3722, UserFeeNotices@
cbp.dhs.gov.
DATES:
SUPPLEMENTARY INFORMATION:
Background
On December 4, 2015, the Fixing
America’s Surface Transportation Act
(FAST Act, Pub. L. 114–94) was signed
into law. Section 32201 of the FAST Act
amended section 13031 of the
Consolidated Omnibus Budget
Reconciliation Act (COBRA) of 1985 (19
U.S.C. 58c) by requiring certain customs
COBRA user fees and corresponding
limitations to be adjusted by the
Secretary of the Treasury (Secretary) to
reflect certain increases in inflation.
Sections 24.22 and 24.23 of title 19 of
the Code of Federal Regulations (19 CFR
24.22 and 24.23) describe the
procedures that implement the
requirements of the FAST Act.
Specifically, paragraph (k) in section
24.22 (19 CFR 24.22(k)) sets forth the
methodology to determine the change in
inflation as well as the factor by which
the fees and limitations will be adjusted,
if necessary. The fees and limitations
subject to adjustment, which are set
forth in Appendix A and Appendix B of
part 24, include the commercial vessel
arrival fees, commercial truck arrival
fees, railroad car arrival fees, private
vessel arrival fees, private aircraft
arrival fees, commercial aircraft and
vessel passenger arrival fees, dutiable
mail fees, customs broker permit user
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
37509
fees, barges and other bulk carriers
arrival fees, and merchandise processing
fees, as well as the corresponding
limitations.
Determination of Whether an
Adjustment Is Necessary for Fiscal Year
2019
In accordance with 19 CFR 24.22, CBP
must determine annually whether the
fees and limitations must be adjusted to
reflect inflation. For fiscal year 2019,
CBP is making this determination by
comparing the average of the Consumer
Price Index—All Urban Consumers, U.S.
All items, 1982–84 (CPI–U) for the
current year (June 2017–May 2018) with
the average of the CPI–U for the
comparison year (June 2016-May 2017)
to determine the change in inflation, if
any. If there is an increase in the CPI of
greater than one (1) percent, CBP must
adjust the customs COBRA user fees and
corresponding limitations using the
methodology set forth in 19 CFR
24.22(k). (19 CFR 24.22(k)). Following
the steps provided in paragraph (k)(2) of
section 24.22, CBP has determined that
the increase in the CPI between the most
recent June to May 12-month period
(June 2017–May 2018) and the
comparison year (June 2016-May 2017)
is 2.063 1 percent. As the increase in the
CPI is greater than one (1) percent, the
customs COBRA user fees and
corresponding limitations must be
adjusted for Fiscal Year 2019.
Determination of the Adjusted Fees and
Limitations
Using the methodology set forth in
section 24.22(k)(2) of the CBP
regulations (19 CFR 24.22(k)), CBP has
determined that the factor by which the
base fees and limitations will be
adjusted is 4.866 percent (base fees and
limitations can be found in Appendix A
and B to part 24 of title 19). In reaching
this determination, CBP calculated the
values for each variable found in
paragraph (k) of 19 CFR 24.22 as
follows:
• The arithmetic average of the CPI–
U for June 2017–May 2018, referred to
as (A) in the CBP regulations, is
247.540;
• The arithmetic average of the CPI–
U for Fiscal Year 2014, referred to as (B),
is 236.009;
• The arithmetic average of the CPI–
U for the comparison year, referred to as
(C), is 242.328;
• The difference between the
arithmetic averages of the CPI–U of the
1 The figures provided in this notice may be
rounded for publication purposes only. The
calculations for the adjusted fees and limitations
were made using unrounded figures, unless
otherwise noted.
E:\FR\FM\01AUN1.SGM
01AUN1
Agencies
[Federal Register Volume 83, Number 148 (Wednesday, August 1, 2018)]
[Notices]
[Pages 37508-37509]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-16440]
[[Page 37508]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Current List of HHS-Certified Laboratories and Instrumented
Initial Testing Facilities Which Meet Minimum Standards To Engage in
Urine Drug Testing for Federal Agencies
AGENCY: Substance Abuse and Mental Health Services Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Department of Health and Human Services (HHS) notifies
federal agencies of the laboratories and Instrumented Initial Testing
Facilities (IITF) currently certified to meet the standards of the
Mandatory Guidelines for Federal Workplace Drug Testing Programs
(Mandatory Guidelines).
A notice listing all currently HHS-certified laboratories and IITFs
is published in the Federal Register during the first week of each
month. If any laboratory or IITF certification is suspended or revoked,
the laboratory or IITF will be omitted from subsequent lists until such
time as it is restored to full certification under the Mandatory
Guidelines.
If any laboratory or IITF has withdrawn from the HHS National
Laboratory Certification Program (NLCP) during the past month, it will
be listed at the end and will be omitted from the monthly listing
thereafter.
This notice is also available on the internet at https://www.samhsa.gov/workplace.
FOR FURTHER INFORMATION CONTACT: Charles LoDico, Division of Workplace
Programs, SAMHSA/CSAP, 5600 Fishers Lane, Room 16N02C, Rockville,
Maryland 20857; 240-276-2600 (voice).
SUPPLEMENTARY INFORMATION: The Department of Health and Human Services
(HHS) notifies federal agencies of the laboratories and Instrumented
Initial Testing Facilities (IITF) currently certified to meet the
standards of the Mandatory Guidelines for Federal Workplace Drug
Testing Programs (Mandatory Guidelines). The Mandatory Guidelines were
first published in the Federal Register on April 11, 1988 (53 FR
11970), and subsequently revised in the Federal Register on June 9,
1994 (59 FR 29908); September 30, 1997 (62 FR 51118); April 13, 2004
(69 FR 19644); November 25, 2008 (73 FR 71858); December 10, 2008 (73
FR 75122); April 30, 2010 (75 FR 22809); and on January 23, 2017 (82 FR
7920).
The Mandatory Guidelines were initially developed in accordance
with Executive Order 12564 and section 503 of Public Law 100-71. The
``Mandatory Guidelines for Federal Workplace Drug Testing Programs,''
as amended in the revisions listed above, requires strict standards
that laboratories and IITFs must meet in order to conduct drug and
specimen validity tests on urine specimens for federal agencies.
To become certified, an applicant laboratory or IITF must undergo
three rounds of performance testing plus an on-site inspection. To
maintain that certification, a laboratory or IITF must participate in a
quarterly performance testing program plus undergo periodic, on-site
inspections.
Laboratories and IITFs in the applicant stage of certification are
not to be considered as meeting the minimum requirements described in
the HHS Mandatory Guidelines. A HHS-certified laboratory or IITF must
have its letter of certification from HHS/SAMHSA (formerly: HHS/NIDA),
which attests that it has met minimum standards.
In accordance with the Mandatory Guidelines dated January 23, 2017
(82 FR 7920), the following HHS-certified laboratories and IITFs meet
the minimum standards to conduct drug and specimen validity tests on
urine specimens:
HHS-Certified Instrumented Initial Testing Facilities
Dynacare, 6628 50th Street NW, Edmonton, AB Canada T6B 2N7, 780-784-
1190, (Formerly: Gamma-Dynacare Medical Laboratories).
HHS-Certified Laboratories
ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY 14624,
844-486-9226.
Alere Toxicology Services, 1111 Newton St., Gretna, LA 70053, 504-361-
8989/800-433-3823, (Formerly: Kroll Laboratory Specialists, Inc.,
Laboratory Specialists, Inc.).
Alere Toxicology Services, 450 Southlake Blvd., Richmond, VA 23236,
804-378-9130, (Formerly: Kroll Laboratory Specialists, Inc., Scientific
Testing Laboratories, Inc.; Kroll Scientific Testing Laboratories,
Inc.).
Baptist Medical Center-Toxicology Laboratory, 11401 I-30, Little Rock,
AR 72209-7056, 501-202-2783, (Formerly: Forensic Toxicology Laboratory
Baptist Medical Center).
Clinical Reference Laboratory, Inc., 8433 Quivira Road, Lenexa, KS,
66215-2802, 800-445-6917.
DrugScan, Inc., 200 Precision Road, Suite 200, Horsham, PA 19044, 800-
235-4890.
Dynacare*, 245 Pall Mall Street, London, ONT, Canada N6A 1P4, 519-679-
1630, (Formerly: Gamma-Dynacare Medical Laboratories).
ElSohly Laboratories, Inc., 5 Industrial Park Drive, Oxford, MS 38655,
662-236-2609.
Laboratory Corporation of America Holdings, 7207 N Gessner Road,
Houston, TX 77040, 713-856-8288/800-800-2387.
Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ
08869, 908-526-2400/800-437-4986, (Formerly: Roche Biomedical
Laboratories, Inc.).
Laboratory Corporation of America Holdings, 1904 TW Alexander Drive,
Research Triangle Park, NC 27709, 919-572-6900/800-833-3984, (Formerly:
LabCorp Occupational Testing Services, Inc., CompuChem Laboratories,
Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical
Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche
Group).
Laboratory Corporation of America Holdings, 1120 Main Street,
Southaven, MS 38671, 866-827-8042/800-233-6339, (Formerly: LabCorp
Occupational Testing Services, Inc.; MedExpress/National Laboratory
Center).
LabOne, Inc. d/b/a Quest Diagnostics, 10101 Renner Blvd., Lenexa, KS
66219, 913-888-3927/800-873-8845, (Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center for Laboratory Services, a Division
of LabOne, Inc.).
MedTox Laboratories, Inc., 402 W. County Road D, St. Paul, MN 55112,
651-636-7466/800-832-3244.
Legacy Laboratory Services--MetroLab, 1225 NE 2nd Ave., Portland, OR
97232, 503-413-5295/800-950-5295.
Minneapolis Veterans Affairs Medical Center, Forensic Toxicology
Laboratory, 1 Veterans Drive, Minneapolis, MN 55417, 612-725-2088.
Testing for Veterans Affairs (VA) Employees Only.
National Toxicology Laboratories, Inc., 1100 California Ave.,
Bakersfield, CA 93304, 661-322-4250/800-350-3515.
One Source Toxicology Laboratory, Inc., 1213 Genoa-Red Bluff, Pasadena,
TX 77504, 888-747-3774, (Formerly: University of Texas Medical Branch,
Clinical Chemistry Division; UTMB Pathology-Toxicology Laboratory).
Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA
91311, 800-328-6942, (Formerly: Centinela Hospital Airport Toxicology
Laboratory).
Pathology Associates Medical Laboratories, 110 West Cliff Dr.,
[[Page 37509]]
Spokane, WA 99204, 509-755-8991/800-541-7891x7.
Phamatech, Inc., 15175 Innovation Drive, San Diego, CA 92128, 888-635-
5840.
Quest Diagnostics Incorporated, 1777 Montreal Circle, Tucker, GA 30084,
800-729-6432, (Formerly: SmithKline Beecham Clinical Laboratories;
SmithKline Bio-Science Laboratories).
Quest Diagnostics Incorporated, 400 Egypt Road, Norristown, PA 19403,
610-631-4600/877-642-2216, (Formerly: SmithKline Beecham Clinical
Laboratories; SmithKline Bio-Science Laboratories).
Redwood Toxicology Laboratory, 3700 Westwind Blvd., Santa Rosa, CA
95403, 800-255-2159.
STERLING Reference Laboratories, 2617 East L Street, Tacoma, WA 98421,
800-442-0438.
US Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson St.,
Fort George G. Meade, MD 20755-5235, 301-677-7085, Testing for
Department of Defense (DoD) Employees Only.
* The Standards Council of Canada (SCC) voted to end its Laboratory
Accreditation Program for Substance Abuse (LAPSA) effective May 12,
1998. Laboratories certified through that program were accredited to
conduct forensic urine drug testing as required by U.S. Department of
Transportation (DOT) regulations. As of that date, the certification of
those accredited Canadian laboratories will continue under DOT
authority. The responsibility for conducting quarterly performance
testing plus periodic on-site inspections of those LAPSA-accredited
laboratories was transferred to the U.S. HHS, with the HHS' NLCP
contractor continuing to have an active role in the performance testing
and laboratory inspection processes. Other Canadian laboratories
wishing to be considered for the NLCP may apply directly to the NLCP
contractor just as U.S. laboratories do.
Upon finding a Canadian laboratory to be qualified, HHS will
recommend that DOT certify the laboratory (Federal Register, July 16,
1996) as meeting the minimum standards of the Mandatory Guidelines
published in the Federal Register on January 23, 2017 (82 FR 7920).
After receiving DOT certification, the laboratory will be included in
the monthly list of HHS-certified laboratories and participate in the
NLCP certification maintenance program.
Charles P. LoDico,
Chemist.
[FR Doc. 2018-16440 Filed 7-31-18; 8:45 am]
BILLING CODE 4160-20-P